Zymeworks completes Theravance Biopharma buyout, adds new assets and revenue streams
Zymeworks has wrapped up its takeover of Theravance Biopharma, adding new drugs and royalties to its portfolio and pushing for steadier revenue.
Zymeworks 1 article
Zymeworks is an antibody and protein-therapeutics company whose biologic strategy centers on multispecific antibody therapeutics, with Azymetric antibody engineering defining a key target, format or immune mechanism. A further layer of its biologics work includes EFECT Fc engineering platform and bispecific HER2 antibody therapy, with HER2-expressing cancer therapeutics providing the disease, target or immune-mechanism context. For entity matching, binding format and drug molecule are separate from the organization; Zymeworks is also associated with antibody-drug conjugate development.